Capecitabine Induced Therapy Related Acute Myeloblastic Leukemia with t(10;11) (q22;q23) in a Patient with Breast Cancer

  • Zübeyde Nur Özkurt Gazi Üniversitesi Tıp Fakültesi
  • Ramazan Öcal Gazi Üniversitesi Tıp Fakültesi
  • Mehmet Sezgin Pepeler Gazi Üniversitesi Tıp Fakültesi
  • Burcu Ülküden Gazi Üniversitesi Tıp Fakültesi
Keywords: Capecitabine, therapy related acute myeloblastic leukemia, breast cancer, t(10, 11)(q22, q23)


Capecitabine is an oral agent that is used either as single agent or in combination therapy. Therapy related acute myeloblastic leukemia after capecitabine use is rarely reported. We presented a 39-year-old woman with metastatic breast cancer. She admitted with acute myelomonocytic leukemia after treating with oral Capecitabine. t(10;11)(q22;q23) was determined in conventional cytogenetic analysis. She achieved complete remission with intensive chemotherapy but relapse developed. She died although the salvage chemotherapy. To our knowledge our patients is the first report with t-AML with t(10;11)(q22;q23) secondary to Capecitabine use for breast cancer treatment. Capecitabine should be carefully used especially in patients with high risk for t-AML.

Author Biographies

Zübeyde Nur Özkurt, Gazi Üniversitesi Tıp Fakültesi
Hematoloji BD Doç. Dr.
Ramazan Öcal, Gazi Üniversitesi Tıp Fakültesi
Hematoloji BD Uzm. Dr.
Mehmet Sezgin Pepeler, Gazi Üniversitesi Tıp Fakültesi
Hematoloji BD Uzm. Dr.
Burcu Ülküden, Gazi Üniversitesi Tıp Fakültesi
Hematoloji BD Uzm. Dr.


Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol 2008; 35: 418-29

Walko CM, Lindley C. Capecitabine: A Review. Clin Ther 2005; 27:23-44

Shapiro S, Hughes G, Al-Obaidi MJ, et al. Acute myeloid leukemia secondary to treatment with capecitabine for metastatic colorectal cancer. Eur J Hematol 2007; 78:543-4

Rashidi A, Man L, Howard JR, et al. Therapy-related acute promyelocytic leukemia after chemoradiotherapy with capecitabine for rectal adenocarcinoma. Leuk Lymphoma 2014; 55: 683-4

Tansley S, Gibbons S. Capecitabine-induced acute myeloid leukaemia. N Z Med J 2009;122:118-28

Zhang YC, Zhou YO, Yan B, et al. Secondary acute promyelocytic leukemia following chemotherapy for gastric cancer: A case report. World J Gastroenterol 2015; 21: 4402-7

Damodaran S, Bellavia T, Sait SNJ, et al. Acute myeloid leukemia secondary to Oxaliplatin treatment for esophageal cancer. Clin Colorectal Cancer 2012; 11: 151-4

Bueso-Ramos CE, Kanagal-Shamanna R, Routbort MJ, et al. Therapy-Related Myeloid Neoplasm. Am J Clin Pathol. 2015;144:207-18

Ono R, Taki T, Taketani T, et al. LCX, leukemia-assciated protein with a CXX domain, is fused to MLL in acute myeloid leukemia with trilinage dysplasia. Cancer Research 2002; 62:4075-80

Lorsbach RB, Moore J, Mathew S, et al. TET1, a member of a novel protein family, is fused to MLL in acutevmyeloid leukemia containing the t(10;11)(q22;q23). Leukemia 2003; 17:637-41

Pigneux A, Labopin M, Maertens J, et al. On Behalf of the Acute Leukemia Working Party EBMT. Outcome of allogeneic hematopietic ste cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-rAML) Leukemia 2015; 29: 2375-81

DiNardo CD, Tang G, Pemmaraju N, et al. Acute myeloid leukemia with t(10;11): a pathological entity with distinc clinical presentation. Clin Lymhoma Myeloma Leuk 2016; 15:47-51

Wolff AC, Blackford AL, Visvanathan K, et al. Risk of Marrow Neoplasms After Adjuvant Breast Cancer Therapy: The National Comprehensive Cancer Network Experience J Clin Oncol 2015; 33: 340–8

Armand P, Kim HT, Mayer E, et al. Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy Bone Marrow Transplant 2010; 45: 1611–7